BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21962244)

  • 21. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Halfdanarson TR; Muders MH; Ames MM
    Pancreas; 2013 Apr; 42(3):411-21. PubMed ID: 23211371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AXL regulates mesothelioma proliferation and invasiveness.
    Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
    Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.
    Pashtan I; Tsutsumi S; Wang S; Xu W; Neckers L
    Cell Cycle; 2008 Sep; 7(18):2936-41. PubMed ID: 18769157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.
    Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yamauchi J; Natsume H; Moriwaki H; Kozawa O
    Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
    Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
    Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
    Ahsan A; Ramanand SG; Whitehead C; Hiniker SM; Rehemtulla A; Pratt WB; Jolly S; Gouveia C; Truong K; Van Waes C; Ray D; Lawrence TS; Nyati MK
    Neoplasia; 2012 Aug; 14(8):670-7. PubMed ID: 22952420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
    Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
    Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
    Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
    Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
    Safavi S; Järnum S; Vannas C; Udhane S; Jonasson E; Tomic TT; Grundevik P; Fagman H; Hansson M; Kalender Z; Jauhiainen A; Dolatabadi S; Stratford EW; Myklebost O; Eriksson M; Stenman G; Schneider-Stock R; Ståhlberg A; Åman P
    Oncotarget; 2016 Jan; 7(1):433-45. PubMed ID: 26595521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
    Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
    BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression.
    Tu Y; Zuo R; Ni N; Eilers G; Wu D; Pei Y; Nie Z; Wu Y; Wu Y; Ou WB
    Cell Cycle; 2018; 17(23):2577-2592. PubMed ID: 30488756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
    Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
    Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
    Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
    Jang WJ; Jung SK; Kang JS; Jeong JW; Bae MK; Joo SH; Park GH; Kundu JK; Hong YS; Jeong CH
    Cancer Sci; 2014 Oct; 105(10):1245-53. PubMed ID: 25117641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.